Home » Topics » BioWorld Science

BioWorld Science
RSS

Idorsia initiates phase III study of aprocitentan for resistant hypertension

June 20, 2018

Kala updates registration plan for KPI-121 for short-term treatment of dry eye disease

June 20, 2018

Can-Fite updates status of phase II trial of namodenoson in advanced HCC

June 20, 2018

Seattle Children's initiates phase I trial of CAR T-cell therapy for pediatric CNS tumors

June 20, 2018

Monalizumab shows promising activity in combination with durvalumab in MSS-CRC

June 20, 2018

Andes-1537 well tolerated in phase I study, dose expansions planned

June 20, 2018

Genentech, Roche and Paraza Pharma patent TRPA1 antagonists

June 20, 2018

Allena Pharmaceuticals completes preclinical proof-of-concept study for ALLN-346

June 20, 2018

Boehringer Ingelheim identifies free fatty acid receptor 1 agonists

June 20, 2018

RC-48-ADC demonstrates promising antitumor activity in patients with metastatic breast cancer

June 20, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.